Freedom Capital raised the firm’s price target on LifeMD (LFMD) to $10 from $8 and keeps a Buy rating on the shares. The company’s Q4 reported confirm a growth reacceleration as its revenue and adjusted EBITDA beat expectations, the analyst tells investors in a research note. The firm sees share upside from LifeMD’s user-retention metrics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD: